Extreme thrombocytosis and cardiovascular surgery: Risks and management

Texas Heart Institute Journal

Volumn 39, Issue 6, 2012, Pages 792-798

  Natelson, Ethan A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Coronary thrombosis prevention and control surgery; Erythromelalgia; Hemorrhage drug therapy; Hydroxyurea therapeutic use; Myeloproliferative disorders genetics pathology; Plateletpheresis; Polycythemia vera blood; Preoperative care methods; Risk factors; Thrombocythemia, Essential complications diagnosis etiology genetics metabolism physiopathology

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANAGRELIDE; ANTIBIOTIC AGENT; CYTARABINE; DIPYRIDAMOLE; GALACTOFLAVIN; HEPARIN; HYDROXYUREA; IRON; METHOTREXATE; PROTEIN TYROSINE KINASE INHIBITOR; QUERCETIN; RIBOFLAVIN; SULFINPYRAZONE; UNCLASSIFIED DRUG; WARFARIN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANEURYSM; ARTERY THROMBOSIS; CARDIOVASCULAR SURGERY; CASE REPORT; CLAUDICATION; CLINICAL FEATURE; CONTINUOUS INFUSION; ERYTHROCYTE COUNT; ERYTHROCYTOSIS; ERYTHROMELALGIA; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEMORRHOID HEMORRHAGE; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MICROCYTIC ANEMIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA; POSTOPERATIVE HEMORRHAGE; REVIEW; SPLENOMEGALY; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREATMENT OUTCOME;

CORONARY THROMBOSIS/PREVENTION & CONTROL/SURGERY; ERYTHROMELALGIA; HEMORRHAGE/DRUG THERAPY; HYDROXYUREA/THERAPEUTIC USE; MYELOPROLIFERATIVE DISORDERS/GENETICS/PATHOLOGY; PLATELETPHERESIS; POLYCYTHEMIA VERA/BLOOD; PREOPERATIVE CARE/METHODS; RISK FACTORS; THROMBOCYTHEMIA, ESSENTIAL/COMPLICATIONS/DIAGNOSIS/ETIOLOGY/GENETICS/METABOLISM/PHYSIOPATHOLOGY;

ADULT; AGED; CARDIOVASCULAR SURGICAL PROCEDURES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELETPHERESIS; POSTOPERATIVE HEMORRHAGE; RISK FACTORS; THROMBOCYTOSIS; THROMBOSIS;

EID: 84874045228     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Beer PA. The pathogenesis of essential thrombocythemia. Curr Opin Hematol 2011;18(5):323-329.
2. Rumi E, Harutyunyan A, Elena C, Pietra D, Klampf l T, Bagienski K, et al. Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. Am J Hematol 2011;86(12):974-979.
3. Michiels JJ, Berneman ZN, Schroyens W, Van Vliet HH. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets 2004;15(2):67-84.
4. Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, Andreasson B. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol 2011;86(2):148-155.
5. Gambichler T, Matip R. Erythromelalgia and livedo reticularis in a patient with essential thrombocythemia, acquired von Willebrand disease, and elevated anti-phospholipid antibodies. Ann Dermatol 2012;24(2):214-217.
6. Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol 2012;87(5):552-554.
7. Bernasconi P, Boni M, Cavigliano PM, Calatroni S, Brusamolino E, Passamonti F, et al. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. Leukemia 2002;16(10):2078-2083.
8. Natelson EA, Pyatt D. Temozolomide-induced myelodysplasia. Adv Hematol 2010;2010:760402. Epub 2010 Mar 4.
9. Ahmed K, Vohra HA, Milne A, Langley SM. Aortic valve replacement in a young patient with essential thrombocytosis. J Cardiothorac Surg 2008;3:5.
10. Ahn IE, Natelson EA, Rice L. Combination treatment of essential thrombocythemia with hydroxyurea and anagrelide. Blood (ASH Annual Meeting Abstracts) 2011;118: Abstract 5177.
11. Das SS, Bose S, Chatterjee S, Parida AK, Pradhan SK. Thrombocytapheresis: managing essential thrombocythemia in a surgical patient. Ann Thorac Surg 2011;92(1):e5-e6.
12. Gutierrez-Martin MA, Araji OA, Miranda N, Barquero JM. Mitroaortic valve replacement after aortic transapical approach failure in a patient with essential thrombocytosis. Interact Cardiovasc Thorac Surg 2010;11(3):360-361.
13. Ruggeri M, Rodeghiero F, Tosetto A, Castaman G, Scognamiglio F, Finazzi G, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 2008;111(2):666-671.
14. Nurkalem Z, Uslu N, Gorgulu S, Eren M. Left main coronary thrombosis with essential thrombocythemia. J Thromb Thrombolysis 2006;22(3):165-167.
15. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006;81(2):159-166.
16. Scholzel BE, Endeman H, Dewilde W, Yilmaz A, de Weerdt O, Ten Berg JM. Cardiac surgery in a patient with essential thrombocythemia: a case report. Neth Heart J 2010;18(7-8):378-380.
17. Yamaguchi K, Hisano M, Sakata M, Minatogawa Y, Suzuki T, Ozawa N, et al. Periodic plateletpheresis during pregnancy in a high-risk patient with essential thrombocythemia. J Clin Apher 2006;21(4):256-259.